HealthPhoto: News18Retatrutide Doubles Weight Loss Compared to Ozempic in Diabetes Trial
In a Phase 3 trial called TRANSCEND-T2D-2, Eli Lilly's experimental weekly injection retatrutide helped people with type 2 diabetes lose an average of 20.1 kg, more than double the weight loss achieved with Ozempic. The trial involved 1,298 adults whose blood sugar was uncontrolled on metformin or SGLT2 inhibitors. Retatrutide is not yet approved anywhere, including India.
News18·



